Georgia BCCPTP Medicaid (2026): Full Coverage for Breast and Cervical Cancer Treatment

::component{type="hero"} title: "Georgia Medicaid for Breast and Cervical Cancer Treatment: The BCCPTP Pathway Through DPH Screening" subtitle: "How the Breast and Cervical Cancer Prevention and Treatment Act of 2000 gives Georgia women diagnosed through the state's Breast and Cervical Cancer Program a standalone Medicaid eligibility category that pays for surgery, chemotherapy, radiation, targeted therapy, immunotherapy, reconstruction, and five-to-ten-year adjuvant hormonal therapy, even when they would not otherwise qualify for Medicaid." ::

::component{type="callout" variant="key-takeaways"} title: "Key takeaways" items:

• "The Breast and Cervical Cancer Prevention and Treatment Program (BCCPTP) is a federal Medicaid eligibility category created by 42 USC 1396a(a)(10)(A)(ii)(XVIII). It gives full Medicaid State Plan coverage to women under 65 who were screened through a CDC-funded National Breast and Cervical Cancer Early Detection Program (NBCCEDP) grantee and diagnosed with breast cancer, cervical cancer, or certain pre-cancerous lesions. In Georgia, the NBCCEDP grantee is the Department of Public Health Breast and Cervical Cancer Program (BCCP)."
• "BCCPTP is not partial coverage. It is the full Georgia Medicaid benefit package: surgery, chemotherapy, radiation, targeted therapy, immunotherapy, pharmacy, mental health, primary care, dental, vision, transportation, durable medical equipment, and reconstruction after mastectomy under the Women's Health and Cancer Rights Act of 1998."
• "Eligibility is established by the BCCP screening intake, not by a separate income or asset determination at Gateway. BCCP itself caps screening income at 250 percent of the federal poverty level, which functions as the de facto income ceiling for BCCPTP. There is no resource test."
• "Coverage runs for the entire duration of active cancer treatment, including adjuvant hormonal therapy such as tamoxifen or an aromatase inhibitor that may last five to ten years after surgery. A recurrence or a new primary cancer restarts the clock."
• "The pathway is gender-specific (women only) and age-bounded (under 65). At 65, a woman transitions to Medicare; Medicaid may continue as a secondary payer for Qualified Medicare Beneficiary or other dual-eligible pathways, but BCCPTP itself ends."
• "Cervical pre-cancers CIN 2/3 and adenocarcinoma in situ qualify under federal law. Breast pre-cancers such as atypical hyperplasia and lobular carcinoma in situ do not. Ductal carcinoma in situ (DCIS) of the breast does qualify because it is treated as a non-invasive carcinoma." ::

The federal pathway: how Congress built a Medicaid category for women diagnosed through public-health screening

By Brevy Care Team · Last verified May 12, 2026

In October 2000, Congress passed the Breast and Cervical Cancer Prevention and Treatment Act of 2000, codified at Public Law 106-354. The law solved a specific policy problem. Since 1990, the Centers for Disease Control and Prevention had operated the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), authorized by the Breast and Cervical Cancer Mortality Prevention Act of 1990 at Public Law 101-354 and 42 USC 300k. NBCCEDP gave grants to state health departments to screen low-income, uninsured, and underinsured women for breast and cervical cancer. The screening worked. By the late 1990s, NBCCEDP grantees in all 50 states, the District of Columbia, five territories, and several tribal organizations were finding thousands of breast and cervical cancers and pre-cancers every year in women who had no insurance and no path to treatment.

The 2000 Act closed that gap. It amended Title XIX of the Social Security Act to add a new optional Medicaid eligibility category, codified at 42 USC 1396a(a)(10)(A)(ii)(XVIII) with implementing regulations at 42 CFR 435.213. States that elected the option (all 50 states, the District of Columbia, and most territories have done so) would extend full Medicaid coverage to any woman who was screened through an NBCCEDP-funded program, diagnosed with breast or cervical cancer or certain pre-cancerous lesions, under 65 years of age, not otherwise eligible for Medicaid, and a US citizen or qualified immigrant. The federal government would reimburse states at the enhanced Title XXI (CHIP) federal medical assistance percentage rather than the regular Title XIX rate. That enhanced match made the option financially attractive for states.

Georgia elected the BCCPTP option through a State Plan Amendment in 2001 and has operated the pathway continuously since. The federal authority works in two parts. First, the Georgia Department of Public Health runs the screening program (BCCP). Second, the Georgia Department of Community Health runs the treatment Medicaid (BCCPTP). The handoff between DPH and DCH is what makes the pathway different from every other Georgia Medicaid category, where eligibility is determined through the Division of Family and Children Services Gateway portal. For BCCPTP, screening through DPH BCCP is itself the eligibility determination. No separate income or asset application is filed; the BCCP enrollment record functions as the eligibility file.

NBCCEDP and Georgia's Breast and Cervical Cancer Program (BCCP): the screening engine that feeds BCCPTP

NBCCEDP is authorized at 42 USC 300k through 300n. Georgia's grantee, BCCP, has been operating continuously since 1994 under O.C.G.A. §31-12-4, which gives the Department of Public Health statutory authority to operate cancer screening programs. BCCP serves all 159 Georgia counties through a network of contracted providers: county health departments, Federally Qualified Health Centers, hospital-based clinics, and qualifying private providers. The program is supplemented by private partnerships with Susan G. Komen, the American Cancer Society, the Avon Foundation, and the Georgia Center for Oncology Research and Education (Georgia CORE).

BCCP screening eligibility is set by federal NBCCEDP rules with some state-level discretion. To be screened through BCCP, a woman must be aged 21 to 64, uninsured or underinsured, and have household income at or below 250 percent of the federal poverty level. The "underinsured" category captures women who have insurance but whose plan does not cover the recommended screening services or whose cost-sharing makes screening practically unaffordable. BCCP provides mammograms (women 40 to 64), clinical breast exams (women 21 to 64), Pap smears and HPV co-testing (women 21 to 64), diagnostic follow-up (ultrasound, MRI, colposcopy, biopsy), and case management.

BCCP serves women across all 159 Georgia counties, connecting uninsured and underinsured women to screening services and, when a qualifying diagnosis is made, to BCCPTP Medicaid for treatment. The bottleneck in this pathway is not capacity; it is awareness. Many uninsured Georgia women do not know that BCCP exists, that screening is free, or that a diagnosis through BCCP automatically triggers a Medicaid eligibility pathway.

Who qualifies: the federal six-factor test and Georgia's implementation

A woman is eligible for BCCPTP Medicaid in Georgia if she meets all six of the following federal criteria, established by 42 USC 1396a(a)(10)(A)(ii)(XVIII) and 42 CFR 435.213.

First, she must be a woman. The program is gender-specific. The statutory language refers to women throughout, and CMS guidance has consistently interpreted the category as limited to those identified as female. Transgender men and non-binary individuals who retain breast or cervical tissue and are screened through BCCP have been enrolled in some state implementations of BCCPTP, including in Georgia, but the eligibility determination is made under the same screening intake rules and the federal language remains gender-specific.

Second, she must be under 65 years of age at the time of BCCPTP enrollment. At 65, most women become eligible for Medicare under either the age-based pathway or the railroad retirement equivalent, and Medicare becomes the primary payer for cancer treatment. BCCPTP is structured to fill the gap before Medicare. A woman who turns 65 mid-treatment transitions to Medicare on her 65th-birthday month, at which point BCCPTP coverage ends. Medicaid may continue as a secondary payer under the Qualified Medicare Beneficiary pathway or other dual-eligible Medicare Savings Program categories, but the BCCPTP designation itself does not extend past 65.

Third, she must not be otherwise eligible for Medicaid. This is what policy people call the "narrow eligibility group" or the "fallback" rule. If a woman is already eligible for Medicaid through SSI, through Pregnancy Medicaid, through MAGI Adult Medicaid (which Georgia did not adopt under the ACA expansion option, narrowing this consideration), through Aged, Blind, and Disabled Medicaid, through Pickle, through Medically Needy with a met spend-down, or through any other category, BCCPTP is not used. The point of BCCPTP is to cover women who would otherwise have no Medicaid pathway. In practice, this means BCCPTP enrollees are usually women between Medicaid pregnancy coverage and Medicare, with no qualifying disability under SSA standards, and with income above the very low income limits Georgia applies to non-MAGI adults.

Fourth, she must be a United States citizen or a qualified immigrant under the Personal Responsibility and Work Opportunity Reconciliation Act of 1996 (PRWORA), 8 USC 1611 through 1646. The five-year bar at 8 USC 1613 applies to BCCPTP. Lawful permanent residents must have held qualified status for five years before becoming eligible. CHIPRA §214, which Georgia adopted only for pregnant women and not for other categories, does not extend to BCCPTP. Refugees, asylees, Cuban-Haitian entrants, Amerasian immigrants, certain trafficking victims, and other exempt qualified immigrant categories are not subject to the five-year bar and can enroll immediately upon arrival or grant of status. Undocumented immigrants and DACA recipients are not eligible for BCCPTP; their only Medicaid pathway is Emergency Medicaid under 42 USC 1396b(v) for an emergency medical condition, which does not cover cancer treatment in most situations.

Fifth, she must have been screened through an NBCCEDP-funded program. In Georgia, that means screening through BCCP. A woman who self-paid for a screening at a private clinic, who was screened through her employer's health plan, or who was screened through any non-NBCCEDP program does not qualify for BCCPTP, even if the screening resulted in a cancer diagnosis. This is the most common reason women who would otherwise qualify miss the pathway. The screening must route through BCCP, not just into a BCCP-network provider. If a woman walks into a Federally Qualified Health Center that participates in BCCP, she must be enrolled in BCCP at intake before screening for the pathway to work. Some FQHCs handle this enrollment automatically; others do not. BCCP retroactive enrollment is possible in limited circumstances if the woman was eligible for BCCP at the time of screening but was not enrolled.

Sixth, she must be diagnosed with a qualifying cancer or pre-cancer. For breast cancer, the qualifying diagnoses are invasive breast cancer (any invasive carcinoma of breast origin) and ductal carcinoma in situ (DCIS), which is treated as a non-invasive breast carcinoma. Atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in situ (LCIS) do not qualify under federal law because they are not considered cancers or carcinomas in situ for BCCPTP purposes. For cervical cancer, the qualifying diagnoses are invasive cervical cancer (any invasive carcinoma of cervical origin) and the cervical pre-cancers CIN 2, CIN 3, and adenocarcinoma in situ (AIS). CIN 1 does not qualify, because it is considered a low-grade lesion that usually regresses without treatment.

How BCCPTP enrollment works: the seven-step process from screening to treatment Medicaid

The pathway from BCCP screening to BCCPTP Medicaid coverage runs through seven steps in Georgia. Understanding these steps matters because each step can be a point of failure, and women who are not enrolled in BCCP at the right moment can lose access to the pathway even after a qualifying diagnosis.

Step one is BCCP enrollment. A woman who is uninsured or underinsured, aged 21 to 64, with household income at or below 250 percent of the federal poverty level, calls BCCP at 1-866-322-2728 or visits a participating county health department, FQHC, or BCCP-contracted provider. She completes the BCCP enrollment form, which collects basic demographic information, household income, and insurance status. Once enrolled, she has a BCCP case file. The case file is the key. Without it, the rest of the pathway does not work.

Step two is screening. The BCCP-contracted provider performs the appropriate screening: mammogram for women 40 to 64 (annually or biennially per USPSTF guidance), clinical breast exam for women 21 to 64, Pap smear for women 21 to 65 (every three years for women 21 to 29 with cytology alone; every five years for women 30 to 65 with co-testing), and HPV co-testing for women 30 to 65. There is no out-of-pocket cost to the woman. BCCP pays the provider directly through its contracted reimbursement schedule.

Step three is diagnostic follow-up. If the screening is abnormal, BCCP also pays for diagnostic workup: diagnostic mammogram, breast ultrasound, breast MRI when indicated, breast biopsy (core needle or excisional), colposcopy with directed biopsy for abnormal Pap, endocervical curettage, and pathology review. The diagnostic workup must also route through BCCP to maintain the pathway integrity. If a woman has an abnormal BCCP screening and then has her biopsy done at a non-BCCP facility self-pay or under hospital charity care, the pathway can still work but it requires careful documentation that the original screening occurred through BCCP.

Step four is diagnosis. The pathologist confirms the diagnosis. For breast cancer, the report identifies whether the lesion is invasive ductal carcinoma, invasive lobular carcinoma, DCIS, or another invasive subtype, along with hormone receptor status (ER, PR), HER2 status, and Ki-67 proliferation index. For cervical cancer, the report identifies whether the lesion is invasive squamous cell carcinoma, invasive adenocarcinoma, CIN 2/3, AIS, or a lower-grade lesion. The diagnosis is the trigger for BCCPTP referral.

Step five is BCCP referral to BCCPTP. The BCCP case manager (typically a nurse or social worker at the screening provider or at DPH) submits a referral packet to the Georgia Department of Community Health BCCPTP unit. The packet includes the BCCP enrollment record, screening date and result, diagnostic workup and biopsy date and result, pathology report confirming a qualifying diagnosis, and confirmation that the woman meets all six federal eligibility factors (woman, under 65, not otherwise Medicaid-eligible, citizen or qualified immigrant, screened through BCCP, diagnosed with a qualifying cancer or pre-cancer).

Step six is BCCPTP eligibility determination by DCH. DCH reviews the referral, confirms citizenship and immigration status through the federal Systematic Alien Verification for Entitlements system, confirms that the woman is not already enrolled in another Medicaid category, and issues the BCCPTP eligibility approval. There is no separate income or asset test conducted by DCH; the BCCP enrollment record (which already verified income at or below 250 percent FPL) functions as the income verification. Coverage typically begins the date of diagnosis or the date the woman first sought diagnostic workup, whichever is earlier, with retroactive coverage available for up to three months before application under 42 USC 1396a(a)(34).

Step seven is enrollment in a Care Management Organization (CMO). Georgia delivers most of its Medicaid services through managed care. Once BCCPTP eligibility is approved, the woman enrolls (or is auto-assigned) into one of Georgia's CMOs. Following DCH's 2025 managed care procurement, new Georgia Families contracts were awarded to CareSource Georgia, Humana, Molina Healthcare, and UnitedHealthcare; the transition timeline is subject to ongoing litigation and may extend into late 2026. The CMO provides the care management and provider network for cancer treatment. The woman has 90 days to switch CMOs after auto-assignment if her preferred oncology provider is not in her assigned CMO's network. After 90 days, she can switch only during the annual open enrollment window unless there is a qualifying event.

What's covered: the full breast cancer treatment scope under BCCPTP

A woman enrolled in BCCPTP Medicaid receives the full Georgia Medicaid State Plan benefit package. There is no separate "cancer benefit" carve-out; the entire State Plan applies. For breast cancer treatment specifically, the covered scope includes the following components, all of which are paid for through the woman's CMO at standard Medicaid reimbursement rates.

Surgical treatment covers lumpectomy (breast-conserving surgery) with sentinel lymph node biopsy or axillary lymph node dissection, mastectomy (simple, modified radical, or radical), bilateral mastectomy when indicated by BRCA mutation status or strong family history, and immediate or delayed breast reconstruction. Reconstruction is mandated by the Women's Health and Cancer Rights Act of 1998 (29 USC 1185b), which requires all health plans that cover mastectomy to also cover reconstruction of the mastectomized breast, surgery and reconstruction of the contralateral breast to produce a symmetrical appearance, prostheses, and treatment of physical complications of mastectomy including lymphedema. Georgia Medicaid is bound by WHCRA and covers all these reconstruction options.

Chemotherapy covers all standard regimens used in breast cancer treatment. For early-stage hormone-receptor-positive, HER2-negative invasive breast cancer, this typically means AC-T (doxorubicin and cyclophosphamide followed by paclitaxel) or TC (docetaxel and cyclophosphamide). For HER2-positive breast cancer, this means TCH (docetaxel, carboplatin, trastuzumab) or AC-THP (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab). For triple-negative breast cancer, this means AC-T with the addition of pembrolizumab in the neoadjuvant or adjuvant setting per KEYNOTE-522 protocols. For metastatic breast cancer, this means a wide range of regimens including capecitabine, eribulin, gemcitabine plus carboplatin, sacituzumab govitecan for triple-negative, and trastuzumab deruxtecan for HER2-positive or HER2-low.

Targeted therapy covers trastuzumab (Herceptin), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla), trastuzumab deruxtecan (Enhertu), CDK4/6 inhibitors palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio), PI3K inhibitor alpelisib (Piqray) for PIK3CA-mutated breast cancer, mTOR inhibitor everolimus (Afinitor), and PARP inhibitors olaparib (Lynparza) and talazoparib (Talzenna) for BRCA-mutated breast cancer. These targeted therapies are expensive (often $10,000 to $20,000 per month at list price) but are fully covered by BCCPTP Medicaid through the woman's CMO formulary, sometimes with prior authorization but without patient cost-sharing.

Immunotherapy covers pembrolizumab (Keytruda) for triple-negative breast cancer in the neoadjuvant and adjuvant setting per KEYNOTE-522 and for PD-L1-positive metastatic triple-negative breast cancer per KEYNOTE-355.

Endocrine therapy is the area where BCCPTP coverage duration matters most. For hormone-receptor-positive breast cancer (about 75 to 80 percent of breast cancers), adjuvant endocrine therapy after surgery and chemotherapy is the foundation of preventing recurrence. Premenopausal women typically receive tamoxifen for 5 to 10 years. Postmenopausal women typically receive an aromatase inhibitor (letrozole, anastrozole, or exemestane) for 5 to 10 years. The MA.17R and ATLAS trials established that 10 years of adjuvant endocrine therapy reduces recurrence and mortality compared to 5 years, so many women now receive the full 10-year course. BCCPTP coverage explicitly continues throughout adjuvant endocrine therapy. A woman diagnosed at age 53 with ER-positive invasive ductal carcinoma may remain on BCCPTP Medicaid through age 63, when her endocrine therapy ends, and then transition to Medicare at 65 with a two-year gap that must be bridged through another pathway.

Radiation therapy covers whole-breast radiation after lumpectomy, hypofractionated whole-breast radiation (the standard of care since the START trials), accelerated partial breast irradiation when indicated, post-mastectomy chest wall radiation, regional nodal irradiation, and palliative radiation for bone metastases or other symptomatic sites.

Supportive care covers anti-emetics (ondansetron, granisetron, palonosetron, NK1 antagonists like aprepitant or rolapitant, dexamethasone, olanzapine), growth factor support (pegfilgrastim, filgrastim, biosimilars), bone-modifying agents (zoledronic acid, denosumab) for bone health during aromatase inhibitor therapy and for bone metastases, anti-anemia agents (epoetin alfa, darbepoetin alfa), pain management including opioids for cancer pain, mental health and psycho-oncology services, palliative care consultations, hospice when curative treatment ends, lymphedema management including physical therapy and compression garments, fertility preservation counseling and procedures when indicated, genetic counseling and BRCA testing, and survivorship care.

What's covered: the full cervical cancer treatment scope under BCCPTP

For cervical cancer and cervical pre-cancers, BCCPTP covers the full treatment range from outpatient pre-cancer procedures through complex multimodality cancer therapy.

Pre-cancer treatment covers loop electrosurgical excision procedure (LEEP), cold knife conization, cryotherapy, laser ablation, and surveillance Pap smears and HPV testing post-treatment. For high-grade cervical pre-cancers (CIN 2/3 and adenocarcinoma in situ), LEEP is the most common outpatient procedure, performed in an office or ambulatory surgery setting under local anesthesia. The procedure itself takes 15 to 30 minutes and is curative for the vast majority of high-grade pre-cancerous lesions. Post-LEEP surveillance includes a follow-up Pap with HPV testing at 6 months and then annual co-testing for at least 25 years per the 2019 ASCCP consensus guidelines.

Surgical treatment for invasive cervical cancer covers simple hysterectomy for early-stage IA1 disease without lymphovascular invasion, radical hysterectomy with pelvic lymphadenectomy for stage IA2 through IIA disease (the standard Wertheim-Meigs procedure or the modified type II radical hysterectomy), trachelectomy with pelvic lymphadenectomy for early-stage disease in women who wish to preserve fertility, and pelvic exenteration for centrally recurrent disease after radiation. Robotic or minimally-invasive radical hysterectomy was the standard until the LACC trial in 2018 showed worse oncologic outcomes; the current standard for radical hysterectomy is open laparotomy.

Concurrent chemoradiation is the cornerstone of treatment for locally-advanced cervical cancer (stages IB3 through IVA). The standard regimen is weekly cisplatin (40 mg/m² IV) for six cycles concurrent with external beam radiation to the pelvis (45 to 50 Gy in 25 fractions) followed by brachytherapy boost (typically high-dose-rate brachytherapy with image-guided treatment planning to a total cumulative equivalent dose of 80 to 90 Gy at point A). BCCPTP covers the full regimen including the brachytherapy, which is administered in specialized centers (Emory University Hospital, Northside Hospital, Augusta University Medical Center, Memorial Health in Savannah, the Medical Center of Central Georgia in Macon, and others).

Systemic therapy for metastatic or recurrent cervical cancer covers platinum-based combination chemotherapy (cisplatin or carboplatin plus paclitaxel), the addition of bevacizumab (Avastin) per GOG-240, immunotherapy with pembrolizumab for PD-L1-positive recurrent or metastatic disease per KEYNOTE-826 and KEYNOTE-A18, and the antibody-drug conjugate tisotumab vedotin (Tivdak) for recurrent or metastatic disease that has progressed on first-line chemotherapy. All of these are covered through the CMO formulary, with prior authorization for the most expensive agents.

Reconstruction and rehabilitation cover vaginal reconstruction when radical surgery has compromised vaginal anatomy, ostomy supplies when pelvic exenteration includes urinary or fecal diversion, pelvic floor physical therapy, sexual health counseling, lymphedema management (lower extremity lymphedema is common after pelvic lymphadenectomy or pelvic radiation), and survivorship care.

Duration of coverage: how long BCCPTP Medicaid lasts

The single most misunderstood feature of BCCPTP is its duration. Many providers and patients assume coverage ends at "the end of treatment," meaning the last chemotherapy infusion or the last radiation fraction. That is wrong. Federal law and Georgia's State Plan both define "during the period in which she requires treatment" to include adjuvant therapy that may continue for many years after the acute treatment phase.

For breast cancer, adjuvant endocrine therapy (tamoxifen, aromatase inhibitors) routinely continues for 5 to 10 years after surgery, chemotherapy, and radiation are complete. BCCPTP coverage continues throughout this period. A woman diagnosed at age 50 with hormone-receptor-positive invasive ductal carcinoma may complete her surgery, chemotherapy, and radiation within 12 months but remain on tamoxifen or letrozole through age 60. Throughout those nine additional years, she remains BCCPTP-eligible and receives full Medicaid coverage. Her annual follow-up with her medical oncologist (typically every six months for the first five years, then annually), her bone density scans (DEXA every two years for women on aromatase inhibitors), her mammograms (annually on the unaffected breast and on the reconstructed breast if reconstruction was performed), and her gynecologic exams (annually, with particular attention to endometrial surveillance for women on tamoxifen) are all covered.

For breast cancer treated with surgery alone (DCIS treated with lumpectomy without radiation or endocrine therapy, for example), coverage typically extends through the active treatment phase plus a defined surveillance period (often two to five years), at which point the woman is reassessed for continuing eligibility. If she is no longer "in treatment" and has no other Medicaid pathway, BCCPTP coverage ends.

For cervical pre-cancers treated with LEEP, conization, or other excisional procedures, coverage typically extends through the procedure itself plus the post-treatment surveillance period (the 25-year surveillance recommended by ASCCP guidelines is not fully covered; BCCPTP coverage typically extends through the high-risk surveillance phase of 5 to 10 years post-LEEP).

For invasive cervical cancer, coverage extends through surgery, chemoradiation, brachytherapy, any subsequent systemic therapy for recurrent or metastatic disease, and survivorship surveillance. There is no defined endpoint; coverage continues as long as the woman is in active treatment or surveillance.

Recurrence or a new primary cancer restarts the coverage clock. A woman who completed her initial BCCPTP treatment and transitioned off coverage can re-enroll in BCCPTP if she is re-screened through BCCP (or if she is referred back to BCCP for diagnostic workup of a new symptom) and diagnosed with a recurrence or a new primary. The eligibility criteria are reapplied at the time of re-enrollment.

The transition at age 65: how BCCPTP and Medicare interact

BCCPTP is age-bounded at 65. The federal statute and 42 CFR 435.213 explicitly limit eligibility to women under 65. When a BCCPTP enrollee turns 65, several things happen in sequence.

First, Medicare becomes available to her if she has the requisite work history (40 quarters of Social Security-covered earnings, either her own or her spouse's). Most women born in the United States who have worked or whose spouses have worked qualify automatically at 65. Premium-free Part A (hospital insurance) begins on the first day of her 65th-birthday month. Part B (medical insurance) requires payment of a monthly premium ($202.90 per month for the standard rate in 2026, more for higher-income beneficiaries). Part D (prescription drug coverage) is purchased separately or as part of a Medicare Advantage plan.

Second, BCCPTP Medicaid coverage ends on the last day of the month she turns 65. The transition is automatic and DCH typically sends a transition notice 60 to 90 days before her 65th birthday.

Third, the woman may be eligible for a Medicare Savings Program through the Aged, Blind, and Disabled Medicaid pathway. If her countable income is at or below 100 percent of the federal poverty level and her countable resources are at or below $9,950 (individual) or $14,910 (couple), she qualifies as a Qualified Medicare Beneficiary (QMB), and Georgia Medicaid pays her Part B premium and all Medicare deductibles and coinsurance for covered services. If her income is between 100 and 120 percent FPL, she qualifies as a Specified Low-Income Medicare Beneficiary (SLMB), and Georgia pays only her Part B premium. If her income is between 120 and 135 percent FPL, she qualifies as a Qualifying Individual (QI), and again Georgia pays only her Part B premium.

Fourth, if the woman is in the middle of active cancer treatment when she turns 65, the transition can create coverage gaps for medications not on the Medicare Part D formulary at the same coverage tier as her CMO formulary, for transportation benefits that Medicare does not cover but Medicaid did, and for behavioral health and dental benefits that Medicare covers less generously than BCCPTP did. Care managers at the woman's CMO and her oncology team typically begin transition planning 90 days before her 65th birthday to identify these gaps and arrange supplemental coverage (Medicare Advantage with prescription drug coverage, a Medigap policy, or full dual-eligibility status under QMB Plus or another MSP category).

Interaction with private insurance, hospital charity care, and Marketplace coverage

A common question is how BCCPTP interacts with other coverage sources. The federal rule is that BCCPTP is for women who are "not otherwise eligible for Medicaid" and who are "uninsured or underinsured." Several interactions are common.

If a woman has private insurance through her employer or her spouse's employer at the time of BCCP screening, she may not be eligible for BCCP screening at all (BCCP serves uninsured and underinsured women). In some cases, BCCP will screen women with private insurance if the insurance does not cover the specific service or if the woman's out-of-pocket cost-sharing makes the service practically unaffordable. If a privately-insured woman is screened through BCCP and diagnosed with a qualifying cancer, she may be eligible for BCCPTP as a secondary payer behind her private insurance, but this is determined case by case.

If a woman has Marketplace coverage (a plan purchased through healthcare.gov with advance premium tax credits and cost-sharing reductions), she is technically "insured" but may meet the "underinsured" definition if her plan has high deductibles or co-insurance. In Georgia, where Medicaid expansion was not adopted under the ACA option (Georgia operates a partial Medicaid expansion known as Pathways to Coverage with a work requirement that is not full ACA expansion), many low-income adults are on Marketplace coverage with significant cost-sharing. A woman on a Marketplace plan who is screened through BCCP and diagnosed with cancer can typically enroll in BCCPTP and either drop her Marketplace plan (if she wants Medicaid to be her primary coverage) or maintain her Marketplace plan with BCCPTP as secondary coverage. The interaction is complex and usually warrants consultation with a navigator or with the Georgia Cancer Resource Center.

If a woman is receiving hospital charity care (financial assistance from a nonprofit hospital under the IRS 501(r) rules that require nonprofit hospitals to maintain financial assistance policies), BCCPTP enrollment usually takes priority. The hospital will bill BCCPTP Medicaid for services and may close the charity care file. Some hospitals operate hybrid models in which they help patients apply for BCCPTP at the time of diagnosis and provide charity care for any gap in BCCPTP coverage.

If a woman is incarcerated, BCCPTP coverage is suspended (not terminated) under federal Medicaid rules at 42 USC 1396a(a)(84) and Georgia State Plan provisions. Treatment during incarceration is the responsibility of the Department of Corrections, but BCCPTP coverage resumes upon release if the woman is still actively in treatment.

Fifteen things that women, providers, and case managers commonly miss about BCCPTP

First, BCCPTP is full Medicaid, not partial. Many providers think it covers only cancer-related services. It does not. It covers the full Georgia Medicaid State Plan: primary care, dental, vision, behavioral health, transportation to non-cancer appointments, pharmacy (including non-cancer medications), and durable medical equipment.

Second, the screening must route through BCCP, not just into a BCCP-network provider. Walking into a Federally Qualified Health Center that happens to participate in BCCP does not enroll a woman in BCCP. She must be enrolled in BCCP at intake, before screening, or her diagnosis will not establish the BCCPTP pathway.

Third, breast pre-cancers other than DCIS do not qualify. Atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in situ (LCIS) are sometimes mistakenly assumed to qualify because they are abnormalities of breast tissue. They do not. Only invasive breast cancer and DCIS qualify.

Fourth, CIN 1 does not qualify. Only CIN 2, CIN 3, and adenocarcinoma in situ qualify on the cervical pre-cancer side. CIN 1 is considered a low-grade lesion that usually regresses without treatment, so federal law does not include it.

Fifth, BRCA-mutation prophylactic mastectomy (preventive mastectomy in a woman with a BRCA mutation who has not been diagnosed with cancer) is not covered by BCCPTP because there is no qualifying cancer diagnosis. The woman would need another Medicaid pathway or private insurance for the preventive surgery.

Sixth, adjuvant endocrine therapy keeps the Medicaid running. A 5- to 10-year course of tamoxifen or an aromatase inhibitor counts as ongoing treatment and BCCPTP coverage continues throughout. This is the single most valuable feature for many breast cancer survivors who would otherwise lose coverage between active treatment and Medicare.

Seventh, recurrence or a new primary restarts the clock. A woman who completes BCCPTP and transitions off can re-enroll if she has a recurrence or a new primary cancer detected through a new BCCP screening or a referral back to BCCP for diagnostic workup.

Eighth, reconstruction after mastectomy is covered, including symmetry surgery on the unaffected breast, prosthetics, and lymphedema management. The Women's Health and Cancer Rights Act mandates this coverage for all health plans that cover mastectomy, and BCCPTP complies fully.

Ninth, BCCPTP routes through DPH BCCP for intake, not through DFCS Gateway. A woman who calls DFCS or visits Gateway asking about Medicaid for cancer treatment may be told she is over the income limit for adult Medicaid (because Georgia did not adopt full ACA expansion) without ever being told that BCCPTP exists. The intake point is the BCCP phone line at 1-866-322-2728 or any BCCP-contracted provider.

Tenth, the income cap is 250 percent FPL, established at BCCP screening, not a separate BCCPTP determination. A woman screened through BCCP at 220 percent FPL who later experiences a household income increase to 280 percent FPL does not lose her BCCPTP eligibility for treatment of a cancer diagnosed through that screening. The eligibility is established at the screening intake.

Eleventh, retroactive coverage to the date of diagnosis (or up to three months before application, whichever is later) is available. Bills incurred for diagnostic workup or initial treatment before BCCPTP enrollment can usually be paid retroactively by Medicaid. The woman should request retroactive coverage during her BCCPTP application.

Twelfth, behavioral health is fully covered. Cancer diagnosis triggers anxiety, depression, and adjustment disorder at rates far above the general population. BCCPTP covers psychiatric medication management, individual and group psychotherapy, and specialized psycho-oncology services where available.

Thirteenth, transportation to medical appointments is covered. Cancer treatment requires frequent visits (chemotherapy infusions, radiation treatments, surgery, post-operative follow-up, lab draws, imaging). Georgia Medicaid covers non-emergency medical transportation through the CMO. Women should arrange transportation through their CMO member services line before each appointment when needed.

Fourteenth, women 65 and older are not eligible for BCCPTP. They are eligible for Medicare. The pathway is for women under 65 only. Women 60 to 64 who are diagnosed mid-treatment will transition to Medicare at 65 and need transition planning 90 days before their birthday.

Fifteenth, undocumented immigrants are not eligible for BCCPTP. They may be eligible for Emergency Medicaid under 42 USC 1396b(v) for an emergency medical condition, but cancer treatment is typically not classified as an emergency medical condition (except in rare circumstances such as a hyperthermic crisis or other immediately life-threatening complication). For uninsured undocumented women diagnosed with cancer, the realistic options are hospital charity care, free or sliding-scale cancer care through CancerCare, Susan G. Komen treatment assistance grants, Georgia CORE patient navigation, and the Avon Foundation. The five-year bar in 8 USC 1613 applies to lawful permanent residents.

Six worked examples

LaToya is 48, lives in Atlanta, and works as a hairstylist with no employer-provided health insurance. Her household income is about $34,000 per year, putting her at roughly 200 percent FPL. She has not had a mammogram since she was 42. A friend at church mentions BCCP, and LaToya calls 1-866-322-2728 and enrolls. She has a screening mammogram at a participating FQHC. The mammogram is abnormal. BCCP pays for a diagnostic mammogram, ultrasound, and core needle biopsy. The biopsy shows invasive ductal carcinoma, ER-positive (90 percent), PR-positive (75 percent), HER2-negative, Ki-67 18 percent. BCCP refers LaToya to BCCPTP. DCH approves BCCPTP Medicaid effective the date of biopsy. LaToya enrolls in UnitedHealthcare, her preferred CMO. She has a partial mastectomy with sentinel lymph node biopsy at Northside Hospital, completes four cycles of TC chemotherapy, undergoes 16 fractions of hypofractionated whole-breast radiation, and starts a 10-year course of letrozole. Her BCCPTP coverage continues throughout the active treatment phase and the 10-year endocrine therapy. She turns 58 when the endocrine therapy ends and reassesses her Medicaid options at that point.

Diane is 52, lives in Macon, and is a part-time school cafeteria worker with no insurance. Her household income is about $19,000 per year. She has a routine screening mammogram through BCCP at the Bibb County Health Department. The mammogram shows pleomorphic calcifications. Stereotactic core biopsy shows DCIS, high-grade, ER-positive. BCCP refers Diane to BCCPTP. She has a lumpectomy at the Medical Center of Central Georgia, completes 16 fractions of whole-breast radiation, and starts a 5-year course of tamoxifen. Her BCCPTP coverage continues throughout the active treatment phase and the 5-year endocrine therapy. She is 57 at the end of endocrine therapy and uses the 8-year window before Medicare to enroll in a Marketplace plan with cost-sharing reductions.

Maria is 35, lives in Athens, and is an undocumented immigrant from Mexico who works in food service for cash wages. Her household income is about $22,000 per year. She has not had a Pap smear in 10 years. A community health worker at the Athens Mercy Health Center suggests she enroll in BCCP. Maria is concerned about immigration consequences. The community health worker explains that BCCP enrollment data is confidential under 8 USC 1644 and not shared with immigration authorities. Maria enrolls and has a Pap. The Pap shows high-grade squamous intraepithelial lesion. Colposcopy with directed biopsy confirms CIN 3. BCCP refers Maria to BCCPTP. DCH reviews the application. Because Maria is undocumented, she is not a qualified immigrant under PRWORA and does not meet the citizenship-or-qualified-immigrant requirement at 42 CFR 435.213. She is not eligible for BCCPTP. Her LEEP procedure is performed at Mercy Health Center under the clinic's sliding-scale fee schedule combined with Susan G. Komen treatment assistance funding. This case illustrates the limit of the BCCPTP pathway for the undocumented population and the importance of charity care and private foundation funding as the alternative pathway.

Ruby is 58, lives in Augusta, and is an uninsured former retail worker recently laid off. Her household income from unemployment benefits is about $24,000 per year. She has occasional spotting between periods. The Richmond County Health Department, a BCCP-contracted provider, enrolls Ruby in BCCP and performs a screening Pap. The Pap shows atypical glandular cells. Endocervical curettage and cervical biopsy show invasive adenocarcinoma of the cervix, stage IIB on imaging (parametrial extension on MRI). BCCP refers Ruby to BCCPTP. She enrolls in Molina Healthcare. She receives concurrent chemoradiation at Augusta University Medical Center: 25 fractions of external beam pelvic radiation, weekly cisplatin chemotherapy, and high-dose-rate brachytherapy boost over five fractions. She has surveillance imaging at three months showing complete response. BCCPTP coverage continues through her active treatment and surveillance phase.

Anita is 42, lives in Savannah, and was treated for early-stage breast cancer 7 years ago when she had private insurance through her then-employer. She has been uninsured for the past three years and has not had follow-up imaging. She develops new bone pain in her lower back and a persistent cough. A friend suggests BCCP. BCCP enrolls Anita and performs a clinical breast exam and diagnostic mammogram. The mammogram shows a new mass in the contralateral breast. Core biopsy confirms a new primary HER2-positive invasive ductal carcinoma. Imaging (CT chest/abdomen/pelvis and bone scan) shows bone and pulmonary metastases, consistent with metastatic disease. BCCP refers Anita to BCCPTP. She enrolls in CareSource Georgia. She starts first-line therapy for HER2-positive metastatic breast cancer: docetaxel, trastuzumab, and pertuzumab for six cycles followed by maintenance trastuzumab plus pertuzumab plus hormonal therapy. After two years on first-line, she develops disease progression and starts trastuzumab deruxtecan (Enhertu) at standard dosing. All systemic therapy, supportive care, mental health services, and palliative care are covered by BCCPTP. Anita's BCCPTP coverage continues as long as she remains in active treatment, which for metastatic disease is typically lifelong.

Sophie is 64, lives in Columbus, and is a self-employed seamstress with no insurance. Her household income is about $28,000 per year. She has a screening mammogram through the Muscogee County Health Department BCCP site. The mammogram shows a suspicious mass. Core biopsy confirms invasive lobular carcinoma, ER-positive, HER2-negative. BCCP refers Sophie to BCCPTP. She enrolls in Humana. She has a mastectomy and sentinel lymph node biopsy at the Piedmont Columbus Regional Cancer Center. Pathology shows a 2.8 cm invasive lobular carcinoma with no nodal involvement. She starts adjuvant chemotherapy with four cycles of TC. Six months into her treatment, she turns 65. Her CMO care manager contacts her 90 days before her birthday to begin transition planning. Sophie enrolls in Medicare effective the first day of her 65th-birthday month: Part A premium-free, Part B with the standard premium, and a Part D plan that covers anastrozole, her planned adjuvant aromatase inhibitor. Her BCCPTP coverage ends on the last day of her 65th-birthday month. Her income (about $28,000 from continuing self-employment) puts her above the QMB and SLMB thresholds but eligible for some Marketplace cost-sharing reductions she does not need given Medicare. She maintains Medicare as primary coverage for the remainder of her treatment and her 10-year adjuvant anastrozole course.

Putting it together: how to use BCCPTP if you or someone you love is diagnosed

The BCCPTP pathway is one of the most generous Medicaid eligibility categories in federal law, and one of the most underused. The reason it is underused is that most Georgia women diagnosed with breast or cervical cancer outside the BCCP screening pipeline never learn about it. Hospital case management departments often default to applying for SSI or Medicaid for the Aged, Blind, and Disabled, both of which have much stricter income and asset rules and much longer determination timelines. A woman who walks into an emergency room with a breast mass, gets a biopsy as an outpatient, and is diagnosed with invasive ductal carcinoma may never be told that if she had been screened through BCCP, she would have qualified for full Medicaid immediately.

The practical guidance is this. If you are a Georgia woman, aged 21 to 64, uninsured or underinsured, and your household income is at or below 250 percent of the federal poverty level, call BCCP at 1-866-322-2728 before you have any non-emergency breast or cervical evaluation. Get enrolled in BCCP. Have your screening through a BCCP-contracted provider. If you are diagnosed with breast cancer, cervical cancer, or a qualifying pre-cancer, the BCCPTP Medicaid pathway will activate automatically through the screening provider's case management.

If you have already been diagnosed with breast or cervical cancer outside the BCCP pipeline, call BCCP anyway. There is a limited window in which retroactive BCCP enrollment can establish the BCCPTP pathway, particularly if your initial screening was through a provider that participates in BCCP even though you were not formally enrolled in BCCP at the time. The case manager will assess your situation.

If you are not eligible for BCCPTP because you are undocumented, over 65, or otherwise outside the federal criteria, call Georgia CORE at 1-404-602-4570, the American Cancer Society at 1-800-227-2345, CancerCare at 1-800-813-4673, or Susan G. Komen Atlanta at 1-404-814-1244. These organizations operate financial assistance programs, transportation grants, treatment assistance funds, and patient navigation services that can bridge gaps for women outside the BCCPTP pathway. Most major Georgia cancer centers (Emory University Hospital, Northside Hospital Cancer Institute, Augusta University Medical Center, Memorial Health, the Medical Center of Central Georgia, the Piedmont Healthcare system) also operate financial assistance programs under IRS 501(r) charity care rules that can provide free or reduced-cost cancer treatment for patients who meet financial need criteria.

For ongoing coverage during the 5- to 10-year adjuvant endocrine therapy phase, work with your CMO care manager and your oncology team to document the ongoing nature of treatment. BCCPTP eligibility is not automatically reverified annually; coverage continues as long as you remain in active treatment, including endocrine therapy. If you ever receive a notice from DCH suggesting your BCCPTP eligibility is ending, contact your oncologist's office to confirm and document your ongoing adjuvant therapy status.

::component{type="accordion" variant="faq"} title: "Frequently asked questions" items:

• question: "What does BCCPTP stand for and how is it different from BCCP?" answer: "BCCP is the Georgia Breast and Cervical Cancer Program, operated by the Department of Public Health since 1994. BCCP is the screening program: it provides mammograms, clinical breast exams, Pap smears, HPV testing, and diagnostic follow-up for uninsured and underinsured Georgia women aged 21 to 64. BCCPTP stands for Breast and Cervical Cancer Prevention and Treatment Program. It is the Medicaid eligibility category created by federal law in 2000 and operated by the Department of Community Health. BCCPTP is the treatment Medicaid that activates when a woman is screened through BCCP and diagnosed with a qualifying cancer or pre-cancer. BCCP feeds women into BCCPTP."
• question: "How long does BCCPTP Medicaid coverage last?" answer: "Coverage lasts the entire duration of active cancer treatment, including adjuvant hormonal therapy. For hormone-receptor-positive breast cancer, adjuvant endocrine therapy (tamoxifen, aromatase inhibitors) routinely continues for 5 to 10 years after surgery and chemotherapy are complete. BCCPTP coverage continues throughout that 5- to 10-year period. For cervical pre-cancer treated with LEEP, coverage typically extends through the procedure plus a 5- to 10-year post-treatment surveillance period. For invasive cervical cancer or metastatic breast cancer, coverage continues indefinitely as long as the woman is in active treatment or surveillance."
• question: "Is BCCPTP only for cancer treatment, or does it cover other healthcare needs too?" answer: "It covers everything. BCCPTP is full Georgia Medicaid State Plan coverage, not a partial cancer-only benefit. Once enrolled, you receive primary care, dental, vision, behavioral health, pharmacy (including non-cancer medications), durable medical equipment, transportation to medical appointments, and emergency care, all in addition to the cancer treatment itself. This is one of the most generous features of the pathway and one of the most commonly missed."
• question: "I am 67 and just diagnosed with breast cancer. Can I get BCCPTP?" answer: "No. BCCPTP is limited to women under 65. At 65, most women become eligible for Medicare, and Medicare becomes the primary coverage for cancer treatment. If your income is low enough, you may also qualify for a Medicare Savings Program (Qualified Medicare Beneficiary, Specified Low-Income Medicare Beneficiary, or Qualifying Individual) that helps with Medicare premiums and cost-sharing. Call Georgia DCH at 1-866-211-0950 or DFCS at 1-877-423-4746 to apply for an MSP. You may also qualify for Medicaid for the Aged, Blind, and Disabled if your income and resources are low enough."
• question: "I have a Marketplace plan with high deductibles. Can I get BCCPTP if I'm diagnosed?" answer: "Possibly. Marketplace coverage with high cost-sharing may qualify you as 'underinsured' for BCCP screening purposes, and a qualifying diagnosis through BCCP may trigger BCCPTP eligibility. The interaction is complex. Call BCCP at 1-866-322-2728 to discuss your specific coverage situation. You may need to drop your Marketplace plan to enroll in BCCPTP as primary coverage, or you may maintain your Marketplace plan with BCCPTP as secondary."
• question: "I am an undocumented immigrant diagnosed with breast cancer. What are my options?" answer: "BCCPTP requires US citizenship or qualified immigrant status under PRWORA. Undocumented immigrants are not eligible. Your options include hospital charity care under IRS 501(r) financial assistance policies (most major Georgia cancer centers participate), free or sliding-scale cancer care through community health centers, treatment assistance grants from Susan G. Komen, CancerCare, the Avon Foundation, and Georgia CORE, and Emergency Medicaid for an emergency medical condition. BCCP screening is available regardless of immigration status (BCCP confidentiality protections apply), so you can still be screened, but BCCPTP treatment Medicaid is not available."
• question: "What if I had my screening through my regular doctor, not BCCP?" answer: "If your screening was not through BCCP, you generally cannot enroll in BCCPTP based on a diagnosis from that screening. The federal rule requires that the diagnosis come from an NBCCEDP-funded program, which in Georgia means BCCP. In limited cases, retroactive BCCP enrollment can establish the pathway, particularly if your initial screening was through a provider that participates in BCCP even though you were not formally enrolled at the time. Call BCCP at 1-866-322-2728 to discuss your situation. If retroactive enrollment is not possible, look for other pathways: hospital charity care, foundation grants, and a Medicaid application through DFCS Gateway for any pathway you may qualify for (Pregnancy Medicaid, ABD, Medically Needy with spend-down)."
• question: "Does BCCPTP cover breast reconstruction after mastectomy?" answer: "Yes. The Women's Health and Cancer Rights Act of 1998 requires all health plans that cover mastectomy to also cover reconstruction. BCCPTP complies fully. Reconstruction can be immediate (at the time of mastectomy) or delayed (months or years later), and includes implant-based reconstruction, autologous tissue reconstruction (DIEP flap, TRAM flap, latissimus flap), nipple-areolar reconstruction, symmetry surgery on the unaffected breast, prosthetics, and lymphedema management."
• question: "What happens if my cancer recurs after BCCPTP coverage ended?" answer: "You can re-enroll in BCCPTP if you are re-screened through BCCP and diagnosed with a recurrence or new primary. The eligibility criteria are reapplied at the time of re-enrollment. If you are still under 65 and otherwise qualify, BCCPTP will cover the new course of treatment. Recurrence or a new primary effectively restarts the coverage clock."
• question: "How do I find out if my doctor participates in BCCP?" answer: "Call BCCP at 1-866-322-2728 and ask for a participating provider near you. BCCP operates through a network of contracted providers in all 159 Georgia counties, including county health departments, Federally Qualified Health Centers, hospital-based clinics, and some private providers. The BCCP website (dph.georgia.gov, search for 'breast and cervical cancer') also maintains a provider directory." ::

::component{type="cta" variant="phone-list"} title: "Who to call" items:

• label: "Georgia Department of Community Health (Medicaid)" phone: "1-866-211-0950" note: "BCCPTP Medicaid enrollment, CMO selection, benefit questions"
• label: "Georgia DPH Breast and Cervical Cancer Program (BCCP)" phone: "1-866-322-2728" note: "BCCP screening enrollment, find a participating provider"
• label: "Georgia Department of Public Health (general)" phone: "1-800-228-9173" note: "General DPH information including BCCP"
• label: "Georgia DFCS (Medicaid application help)" phone: "1-877-423-4746" note: "For non-BCCPTP Medicaid pathways such as ABD or Medically Needy"
• label: "American Cancer Society (Georgia)" phone: "1-800-227-2345" note: "Patient navigation, transportation grants, treatment information"
• label: "Susan G. Komen Atlanta" phone: "1-404-814-1244" note: "Treatment assistance grants, support services for breast cancer"
• label: "Georgia CORE (Center for Oncology Research and Education)" phone: "1-404-602-4570" note: "Oncology resource navigation, clinical trial referrals"
• label: "CancerCare" phone: "1-800-813-4673" note: "Treatment assistance grants, counseling, financial assistance"
• label: "Avon Foundation Breast Care Fund" phone: "1-866-505-2866" note: "Breast cancer treatment financial assistance"
• label: "Atlanta Legal Aid Society" phone: "1-404-524-5811" note: "Free legal help for low-income Georgians, Medicaid appeals"
• label: "Northside Hospital Cancer Institute (Atlanta)" phone: "1-404-845-5555" note: "Major Atlanta cancer center, financial assistance program"
• label: "Emory Winship Cancer Institute (Atlanta)" phone: "1-888-946-7447" note: "NCI-designated comprehensive cancer center, financial counseling" ::

Brevy maintains this guide as part of our ongoing coverage of Georgia Medicaid pathways for eldercare and women's health. We track updates from the Centers for Medicare and Medicaid Services, the Georgia Department of Community Health, and the Georgia Department of Public Health Breast and Cervical Cancer Program, and we revise this guide as policies, dollar figures, and program operations change. The information here reflects federal and Georgia state policy as of May 12, 2026. You can find related Brevy guides on Georgia Medicaid for pregnancy coverage, family planning, covered services, managed care plans, and the main Georgia Medicaid hub at brevy.com.

Find personalized help navigating Georgia Medicaid cancer coverage at brevy.com.

This guide is for educational purposes only and is not legal, medical, or financial advice. Eligibility determinations are made by the Georgia Department of Community Health and the Georgia Department of Public Health Breast and Cervical Cancer Program. For your specific situation, contact BCCP at 1-866-322-2728 or DCH at 1-866-211-0950.